Table 2. The efficacy of c-Met inhibitor in advanced or metastatic NSCLC treatment.
| Year | Author | OS | PFS | ORR | DCR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Target arm (months)* | Control arm (months)* | HR [95% CI] | Target arm (months)* | Control arm (months)* | HR [95% CI] | Target arm** | Control arm** | Target arm*** | Control arm*** | ||
| 2014 | Hirsch | NA | NA | 1.27 [0.69–2.32] | 4.9 | 4.9 | 0.95 [0.63–1.43] | 22/55 | 23/54 | NA | NA |
| 2015 | Scagliotti | 8.5 [7.1–9.3] | 7.8 [7.0–9.0] | 0.98 [0.84–1.14] | 3.6 [2.8–3.7] | 1.9 [1.9–2.0] | 0.74 [0.64–0.85] | 54/526 | 34/522 | 241/526 | 167/522 |
| 2011 | Sequist | 8.6 [7.0–10.3] | 6.9 [5.6–10.4] | 0.87 [0.59–1.27] | 3.8 [3.2–5.4] | 3.3 [1.9–3.7] | 0.81 [0.57–1.16] | 7/74 | 5/72 | 49/74 | 39/72 |
| 2013 | Shaw | 20.3 [18.1-NR] | 22.3 [18.6-NR] | 1.02 [0.68–1.54] | 7.7 [6.0–8.8] | 3.0 [2.6–4.3] | 0.49 [0.37–0.64] | 113/173 | 34/174 | 145/173 | 97/174 |
| 2014 | Solomen | NA | NA | 0.82 [0.54–1.26] | 10.9 [8.3–13.9] | 7.0 [6.8–8.2] | 0.45 [0.35–0.60] | 128/172 | 77/171 | 157/172 | 140/171 |
| 2013 | Spigel | 8.9 | 7.4 | 0.80 [0.50–1.28] | 2.2 | 2.6 | 1.09 [0.73–1.62] | 4/69 | 2/68 | NA | NA |
| 2014 | Spigel | 6.8 [6.1–7.5] | 9.1 [7.7–10.2] | 1.27 [0.98–1.65] | 2.7 | 2.6 | 0.99 [0.81–1.20] | 21/250 | 24/249 | NA | NA |
| 2014 | Wakelee1 | NA | NA | NA | NA | NA | 1.25 [0.80–1.95] | NA | NA | NA | NA |
| 2014 | Wakelee2 | NA | NA | NA | NA | NA | 1.23 [0.81–1.86] | NA | NA | NA | NA |
| 2015 | Yoshioka | 12.7 [10.0–15.7] | 11.1 [9.5–12.6] | 0.89 [0.67–1.18] | 2.9 [2.0–3.8] | 2.0 [1.2–3.4] | 0.72 [0.54–0.95] | 10/153 | 13/154 | 49/153 | 60/154 |
Abbreviations: NA - Not available; NR - Not reached; OS - Overall survival; PFS - Progression-free survival; ORR - Objective response rate; DCR - Disease control rate; HR - Hazard ratio. *The data were presented as median [95% CI] if 95% CI was available. If not, only median was listed. **The data were presented as subjects with objective response/total subjects in an arm. ***The data were presented as subjects with disease control/total subjects in an arm.